Navigation Links
Positive results from phase 1 clinical trials of cuprindro

Medical Therapies Limited today announced that it has completed its first in human clinical trial of Cuprindo™ with interim results from patient diaries indicating that Cuprindo™ is safe and well tolerated.

The trial subjects, healthy volunteers, reported 100% compliance with the dosing protocol which involved application of Cuprindo™ suppositories twice daily over a seven day period. In addition, post-trial colonoscopy on the subjects uncovered healthy mucosa and no evidence of rectal inflammation or ulceration.

The safety trial was conducted in preparation for a planned efficacy study in proctitis patients.

The trial has been a success confirming our pre-clinical safety information on Cuprindo™ and it paves the way for our efficacy study in patients with proctitis, said Medical Therapies Chief Executive Officer Maria Halasz.

While the trial was not geared to assess Cuprindo™s systemic efficacy, one subject reported relief in chronic joint pain after Day 4 of the trial. Results of the full biochemical analysis of the trial assays including information on systemic absorption characteristics of Cuprindo™ are expected in the coming weeks.

Proctitis is a debilitating disease characterised by inflammation and ulceration of the colon, resulting in tiny open sores that can bleed and produce mucus. Symptoms of the disease include chronic diarrhoea, bloody stools and, in severe cases, faecal incontinence.

Current treatments such as corticosteroids and immuno-modulators can cause serious side effects and provide no relief for up to 30% of proctitis patients. A topically applied safe treatment, such as a Cuprindo™ suppository, could provide a much needed alternative for the 1 in 60 people suffering from the disease.


Contact: Dr. Stephanie Williams
Research Australia

Page: 1

Related medicine news :

1. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive
2. HPV-positive head and neck cancer patients fare better than HPV-negative patients
3. HPV-Positive Head and Neck Cancers Fare Better
4. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
5. Seeing our spouses more negatively might be a positive
6. Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
7. Eating out can have both positive and negative impact on obesity
8. Medco CEO Reiterates Guidance, Positive Outlook for 2008
9. Brain Turns to Positive Thoughts When Faced With Death
10. Anthracyclines improve survival in HER2-positive breast cancer patients
11. Six Positive Predictions for 2008, from SuperLife World Service
Post Your Comments:
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... has collaborated with Women’s Web – an online resource for Indian women ... mental and emotional well-being relationship, life balance, stress, professional development, and lifestyle. ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... Vegas, NV (PRWEB) , ... November 25, 2015 , ... ... invites patients to learn more about hair loss treatment with the Capillus272™ Pro laser ... an effective solution for thicker and fuller hair, without the need for surgery, prescription ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Israel , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused ... treatment of various clinical conditions, today announced the closing ... American Depository Shares ( ADSs ), each representing 20 ... up to 3,158,900 ADSs. The ADSs and warrants were ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... today announced that Chief Executive Officer Antonius Schuh, Ph.D., ... 27 th Annual Piper Jaffray Healthcare Conference. ... the New York Palace Hotel in New ... 1:30 p.m. EST. Mr. Schuh will be available for ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: